Biosimilars in Endocrine Practice: From Insulin to Non-Insulin Agents

Biosimilars in Endocrine Practice: From Insulin to Non-Insulin Agents
Current Practices and Future Perspectives

Wednesday, June 21, 2023 |7:30 pm - 8:45 pm ET

Facilitated by Dr. Robert Goldberg, Drs. Ally Prebtani and Rose Yeung will describe the regulation of biosimilar drugs in Canada, review effectiveness and safety of currently available biosimilars in endocrinology, and discuss techniques for effective communication with patients when switching to biosimilars.

Faculty
Dr. Robert Goldberg, University of Toronto, Toronto (Chair)
Dr. Rose Yeung, University of Alberta, Edmonton (Speaker)
Dr. Ally Prebtani, McMaster University, Hamilton (Speaker)
Dr. Elizabeth Rosolowsky, University of Alberta, Edmonton (CSEM CPD Chair)

At the end of this session participants will be able to:

• Describe the monitoring, safety, and effectiveness of biosimilar drugs in Canada
• Summarize the availability and evidence base for the use of insulin biosimilars in Canada
• Describe the availability and evidence base for the use of biosimilars in general endocrine conditions
• Review practical aspects of prescribing biosimilars
  

This session is free for CSEM members and $100 for non-members. 
If you have not yet renewed your CSEM membership for 2023, you can renew now.

This program is co-developed with Viatris and planned independently by CSEM to achieve scientific integrity, validity and balance.